Vital launches new version of advanced visualization software

Vital Images Inc. has released Vitrea2, Version 3.7, the company's latest software for 2D, 3D and 4D visualization analysis.
   
Vitrea 2, Vital Images' flagship software, creates interactive 2D, 3D and 4D images from 2D information generated by CT, MR and PET scanners. The new release features Cardiac Functional Analysis (CFA), CT Lung options and an enhanced CT colonography application.
   
The CFA option visualizes a beating heart in 2D and 3D. Further, CFA measures the ejection fraction of the left ventricle. When used with Vital Images' CT Cardiac option, cardiologists can fully evaluate cardiac function in the CT environment, the company said.
   
The CT Lung application assists in lung cancer diagnosis, treatment and follow-up comparisons, Vital Images said. For example, a temporal comparison capability tracks changes in lung condition over time. The nodule probe tool automatically provides the dimension and volume of a nodule with a single click.
   
In addition, Version 3.7 includes enhancements to InnerviewGI, the company's CT colon software. The updated InnerviewGI option includes improvements to its hands-off fly-through capability that make it easier to examine the colon, along with the ability to move between 2D and 3D images with greater ease.
   
The American College of Radiology Imaging Network (ACRIN), a cooperative group that conducts cancer-related clinical trials, is using this version of InnerviewGI in a major clinical trial comparing CT colonography to traditional colonoscopy, Vital Images said.

Around the web

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.